Arrowhead's Plozasiran Hits Primary Endpoints in Phase 3 Trials for Severe Hypertriglyceridemia
Event summary
- Arrowhead's Phase 3 SHASTA-3 and SHASTA-4 trials for plozasiran in severe hypertriglyceridemia met primary endpoints, showing median triglyceride reductions of 79% and 81% respectively.
- Plozasiran reduced acute pancreatitis events by 78% in the broad study population and 100% in high-risk patients with triglycerides above 880 mg/dL.
- Arrowhead plans to file a supplemental new drug application (sNDA) for plozasiran in the U.S. before the end of 2026.
- Full results will be presented at the European Society of Cardiology Congress on August 30, 2026.
The big picture
Arrowhead's positive Phase 3 results for plozasiran position it as a potential best-in-class therapy for severe hypertriglyceridemia, a condition with limited treatment options. The data supports Arrowhead's strategy to expand the use of plozasiran beyond its current approval for familial chylomicronemia syndrome (FCS). The upcoming regulatory filings and presentations will be critical in determining the drug's market potential and competitive positioning.
What we're watching
- Regulatory Approval Timeline
- The pace at which Arrowhead secures regulatory approvals for plozasiran in severe hypertriglyceridemia across global geographies.
- Market Competition
- How Arrowhead's plozasiran will compete with existing and emerging therapies for severe hypertriglyceridemia.
- Commercialization Strategy
- Whether Arrowhead can effectively commercialize plozasiran, leveraging its existing approvals and partnerships.